ApoE isoforms differentially regulates cleavage and secretion of BDNF

Abstract Apolipoprotein E4 (ApoE4) is a major genetic risk factor for sporadic or late onset Alzheimer’s disease (AD). Brain-derived neurotrophic factor (BDNF) is decreased by 3 to 4-fold in the brains of AD patients at autopsy. ApoE4 mice also have reduced BDNF levels. However, there have been no r...

Full description

Bibliographic Details
Main Authors: Abhik Sen, Thomas J. Nelson, Daniel L. Alkon
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Molecular Brain
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13041-017-0301-3
_version_ 1819212794698924032
author Abhik Sen
Thomas J. Nelson
Daniel L. Alkon
author_facet Abhik Sen
Thomas J. Nelson
Daniel L. Alkon
author_sort Abhik Sen
collection DOAJ
description Abstract Apolipoprotein E4 (ApoE4) is a major genetic risk factor for sporadic or late onset Alzheimer’s disease (AD). Brain-derived neurotrophic factor (BDNF) is decreased by 3 to 4-fold in the brains of AD patients at autopsy. ApoE4 mice also have reduced BDNF levels. However, there have been no reports relating the different ApoE isoforms or AD to differential regulation of BDNF. Here we report that in the hippocampal regions of AD patients both prepro-BDNF and pro-BDNF expression showed a 40 and 60% decrease respectively compared to that expression in the hippocampi of age-matched control patients. We further report that ApoE isoforms differentially regulate maturation and secretion of BDNF from primary human astrocytes. After 24 h, ApoE3 treated astrocytes secreted 1.75- fold higher pro-BDNF than ApoE2-treated astrocytes, and ApoE2-treated astrocytes secreted 3-fold more mature-BDNF (m-BDNF) than ApoE3-treated astrocytes. In contrast, ApoE4-treated cells secreted negligible amounts of m-BDNF or pro-BDNF. ApoE2 increased the level of intracellular pre-pro BDNF by 19.04 ± 6.68%, while ApoE4 reduced the pre-pro BDNF by 21.61 ± 5.9% compared to untreated cells. Similar results were also seen in ApoE2, ApoE3 or ApoE4 treated cells at 4 h. Together, these results indicate that an ApoE2 or ApoE3 mediated positive regulation of BDNF may be protective while ApoE4 related defects in BDNF processing could lead to AD pathophysiology. These interactions of the ApoE isoforms with BDNF may help explain the increased risk of AD associated with the ApoE4 isoform.
first_indexed 2024-12-23T06:48:38Z
format Article
id doaj.art-c94320204fe84a70bcded0f6b6c7f96c
institution Directory Open Access Journal
issn 1756-6606
language English
last_indexed 2024-12-23T06:48:38Z
publishDate 2017-06-01
publisher BMC
record_format Article
series Molecular Brain
spelling doaj.art-c94320204fe84a70bcded0f6b6c7f96c2022-12-21T17:56:29ZengBMCMolecular Brain1756-66062017-06-011011710.1186/s13041-017-0301-3ApoE isoforms differentially regulates cleavage and secretion of BDNFAbhik Sen0Thomas J. Nelson1Daniel L. Alkon2Blanchette Rockefeller Neurosciences InstituteBlanchette Rockefeller Neurosciences InstituteBlanchette Rockefeller Neurosciences InstituteAbstract Apolipoprotein E4 (ApoE4) is a major genetic risk factor for sporadic or late onset Alzheimer’s disease (AD). Brain-derived neurotrophic factor (BDNF) is decreased by 3 to 4-fold in the brains of AD patients at autopsy. ApoE4 mice also have reduced BDNF levels. However, there have been no reports relating the different ApoE isoforms or AD to differential regulation of BDNF. Here we report that in the hippocampal regions of AD patients both prepro-BDNF and pro-BDNF expression showed a 40 and 60% decrease respectively compared to that expression in the hippocampi of age-matched control patients. We further report that ApoE isoforms differentially regulate maturation and secretion of BDNF from primary human astrocytes. After 24 h, ApoE3 treated astrocytes secreted 1.75- fold higher pro-BDNF than ApoE2-treated astrocytes, and ApoE2-treated astrocytes secreted 3-fold more mature-BDNF (m-BDNF) than ApoE3-treated astrocytes. In contrast, ApoE4-treated cells secreted negligible amounts of m-BDNF or pro-BDNF. ApoE2 increased the level of intracellular pre-pro BDNF by 19.04 ± 6.68%, while ApoE4 reduced the pre-pro BDNF by 21.61 ± 5.9% compared to untreated cells. Similar results were also seen in ApoE2, ApoE3 or ApoE4 treated cells at 4 h. Together, these results indicate that an ApoE2 or ApoE3 mediated positive regulation of BDNF may be protective while ApoE4 related defects in BDNF processing could lead to AD pathophysiology. These interactions of the ApoE isoforms with BDNF may help explain the increased risk of AD associated with the ApoE4 isoform.http://link.springer.com/article/10.1186/s13041-017-0301-3Alzheimer’s disease (AD)Apolipoprotein E (ApoE)Brain-derived neurotrophic factor (BDNF)
spellingShingle Abhik Sen
Thomas J. Nelson
Daniel L. Alkon
ApoE isoforms differentially regulates cleavage and secretion of BDNF
Molecular Brain
Alzheimer’s disease (AD)
Apolipoprotein E (ApoE)
Brain-derived neurotrophic factor (BDNF)
title ApoE isoforms differentially regulates cleavage and secretion of BDNF
title_full ApoE isoforms differentially regulates cleavage and secretion of BDNF
title_fullStr ApoE isoforms differentially regulates cleavage and secretion of BDNF
title_full_unstemmed ApoE isoforms differentially regulates cleavage and secretion of BDNF
title_short ApoE isoforms differentially regulates cleavage and secretion of BDNF
title_sort apoe isoforms differentially regulates cleavage and secretion of bdnf
topic Alzheimer’s disease (AD)
Apolipoprotein E (ApoE)
Brain-derived neurotrophic factor (BDNF)
url http://link.springer.com/article/10.1186/s13041-017-0301-3
work_keys_str_mv AT abhiksen apoeisoformsdifferentiallyregulatescleavageandsecretionofbdnf
AT thomasjnelson apoeisoformsdifferentiallyregulatescleavageandsecretionofbdnf
AT daniellalkon apoeisoformsdifferentiallyregulatescleavageandsecretionofbdnf